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ABSTRACT: Biosensors and nanoscale analytical tools have shown huge growth in
literature in the past 20 years, with a large number of reports on the topic of
‘ultrasensitive’, ‘cost-effective’, and ‘early detection’ tools with a potential of ‘mass-
production’ cited on the web of science. Yet none of these tools are commercially
available in the market or practically viable for mass production and use in
pandemic diseases such as coronavirus disease 2019 (COVID-19). In this context,
we review the technological challenges and opportunities of current bio/chemical
sensors and analytical tools by critically analyzing the bottlenecks which have
hindered the implementation of advanced sensing technologies in pandemic
diseases. We also describe in brief COVID-19 by comparing it with other pandemic
strains such as that of severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS) for the identification of features that enable
biosensing. Moreover, we discuss visualization and characterization tools that can
potentially be used not only for sensing applications but also to assist in speeding
up the drug discovery and vaccine development process. Furthermore, we discuss the emerging monitoring mechanism,
namely wastewater-based epidemiology, for early warning of the outbreak, focusing on sensors for rapid and on-site analysis of
SARS-CoV2 in sewage. To conclude, we provide holistic insights into challenges associated with the quick translation of
sensing technologies, policies, ethical issues, technology adoption, and an overall outlook of the role of the sensing
technologies in pandemics.
KEYWORDS: nanosensors, nanoplasmonics, sewage sensors, microfluidics, atomic force microscopy, X-ray diffraction, electron microscopy,
point-of-care-technologies, COVID-19, pandemics
In the last 15 years, humans have witnessed 5 pandemicdiseases, severe acute respiratory syndrome (SARS), Swineflu, Ebola, Middle East respiratory syndrome (MERS), and
coronavirus disease 2019 (COVID-19), where both MERS and
COVID-19 are actively present within our community, with
the latter having more severe complications and infection rates
in recent times. COVID-19 is an infectious disease caused by
the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV2) virus, which was actively revealed in Wuhan, China in
December 2019 and later sequenced in January 2020.1,2 In just
a period of 2 months (March 2020), the disease had spread to
90% of the countries on our planet. In parallel, there remains a
great interest in the biosensors and nanoscale visualization/
characterization tools such as the electron microscopy (EM),
atomic force microscopy (AFM), and X-ray diffraction (XRD)
for the early detection and revealing prognostic features of a
given pathogen.3,4 Recent advances have also extended the use
of these advanced sensing techniques into the development of
high-throughput devices capable of screening a large number
of candidate compounds for quick drug discovery and vaccine
development during pandemics.5−7 Most of the latest sensors
currently available in both academia and industry are based on
the electrical or optical transduction methods.8 These include
single-molecule sensors,9 wearable devices,10 ingestible capsu-
les,11 disposable screen-printed electrodes,12 and hand-held
portable instruments13 which could actively detect the
infectious disease-causing pathogen at an early stage of the
infection. Nevertheless, despite their vast availability and well-
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known advantages in academia, the full potential of the
biosensing and characterization tools is yet to be harnessed in
on-site applications, such as during the outbreak of an
infectious disease. Certainly, there are scientific challenges
and opportunities for bio/chemical sensors before they can live
up to the expectation of accurate, precise, and early diagnosis
of emerging diseases. It is in this context that we present an
analysis of the state of art instruments and technologies, in
particular concerning COVID-19, for the detection and
analysis of pandemic strains. In general, we can segregate the
detection of viruses into three main categories: (1) direct
detection of the virus, (2) viral RNA/DNA detection, and (3)
antibody detection.
These sensing strategies are further complemented by the
aforementioned surface visualization/characterization tools
(AFM, EM, XRD) presenting a complete package of
technologies that can potentially be used for diagnosis,
prognosis, drug discovery, drug analysis, and disease spread
surveillance, all of which are vital for ensuring good community
health.14,15 A general overview of these groups including their
mechanisms is discussed in Table 1. It is also obvious that for
quick technology development, such as for the development of
biosensors for COVID-19, it is essential to build on the
existing scientific evidence for the use of technology in similar
applications. Therefore, we begin by highlighting similarities
and differences between other RNA viral infections from the
perspective of understanding the COVID-19 disease and
subsequent technology development to serve the required
demand for sensing and characterization of the SARS-CoV2
virus.
SIMILARITY OF SARS-COV-2 WITH OTHER VIRAL
STRAINS
COVID-19 disease is highly contiguous as its transmission is
encouraged by airborne droplets and touch-based human to
human contact.16 Common symptoms of this disease are
similar to influenza, and therefore, it is not trivial to rapidly
detect the disease accurately. Comparative analysis of the
SARS-CoV2 with other epidemic viral strains serves as
background information on which researchers can build
upon to create potential technologies to quickly address the
demands of disease control in an emergency.15 While there are
several similarities and differences between these viruses, here
we focus only on those features which will help researchers
working in the field of biosensors and surface visualization/
characterization to develop strategies for accurate detection
and morphological analysis of SARS-CoV2. One striking
similarity between SARS-CoV2 virus and influenza, H1NI,
SARS-CoV, and MERS viruses is that all contain RNA as their
genetic material, therefore also known as RNA viruses.
Compared to DNA viruses, RNA viruses are technically
more virulent as they infect cells by injecting RNA which
quickly transcribes and replicates viral proteins in the host
cell.17 This also makes it extremely challenging to detect a
RNA virus at an early stage of the infection. Cell culture and
nucleic acid-based tests have been the gold standard since their
inception as compared to all other techniques.18
However, unlike the DNA viruses which have polymerase
machinery, the nucleic acid tests for RNA viruses include
additional steps of reverse translation of RNA to DNA before it
is amplified.30 Structurally, as viruses responsible for COVID-
19, SARS, and MERS outbreaks belong to the same category of
beta coronavirus family, these viruses are mostly spherical, but
sometimes pleomorphic in shape.31,32 The average diameter of
these viruses is 125 nm, where their capsid covering the genetic
material is around 85 nm and glycoprotein spikes on the
surface of the capsid are roughly 20 nm;33 see more out of
scale structural features of SARS-CoV2 virus in Figure 1.
Comparing genetic characteristics of the SARS-CoV2 virus
with other viruses may also provide useful insights to develop
sensing strategies for the early detection of COVID-19. For
example, untranslated regions (UTR) of the RNA, both at 5
prime and 3 prime ends are involved in the binding of the
cellular proteins.34 The detailed arrangement of coding regions
of coronaviruses is given in Figure 2. In addition, the
mechanism of how coronaviruses infect cells can also be
useful for developing sensors for analyzing the disease
mechanism and drug discovery. In brief, the SARS-CoV2
virus enters a given cell via protein−protein interactions where
the glycoprotein spikes bind to the angiotensin-converting
enzyme 2 (ACE2) on the cell surface.34 This attachment of the
virus on the cell and further entry into the cell is assisted by
protease enzyme called TMPRSS2. After the entry of the
SARS-CoV2 virus into the cells, the RNA quickly translates
Table 1. Categorization of Biosensing Strategies and Surface Characterization Techniques for Virus Detection
applications
mechanism diagnosis prognosis
drug
discovery
drug
analysis
direct detection of virus complete virus is detected individually using biosensors or more commonly by Petri dish-
based cell culture techniques18,19
X X − −
viral RNA/DNA detection RT-PCR, PCR principles applied either in conventional nucleic acid formats (with
fluorescence or radioactive labels) or using advanced techniques such as LSPR, SPR,
QCM, and other potentiometric sensing techniques20−22
X X X −
antibody/antigen detection microwell-based bioassays using absorbance readers and several optical and electronic
biosensors which essentially measure the binding kinetics of the biomolecule of
interest23
− X X X
surface characterization
tools as complementary
sensing techniques
AFM high-resolution scanning probe microscopy with a resolution 1000 times smaller than the
optical diffraction limit used for investigating surface properties of viruses in the order
of fraction of a nanometer24,25
− X X X
EM the surface of a virus is imaged with a focused beam of electrons to identify topographical
features26
− X X X
XRD crystallographic features of virus are mapped to determine 3D structures of the
viruses27,28
− − X X
a‘X’ denotes suitability of application and ‘−’ indicates application not applicable. In the application column, we refer to diagnosis as a quick
detection either for in use in hospital or self-testing. Note that visualization tools can still be used for diagnosis but are deemed unsuitable for quick
detection.
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into proteins, including the RNA synthesis in the cytoplasm by
viral replication.31
CURRENT DETECTION AND TRACING TECHNOLOGIES
FOR COVID-19
Current detection for COVID-19 is primarily based on the
combination of two or more techniques which include RT-
PCR, chest X-ray, computed tomography (CT) scans, and the
detection of some common biomarkers in the blood.35 These
biomarker tests include identification of elevated levels of the
C-reactive protein, low procalcitonin, low lymphocyte counts,
and high concentration of interleukin 6 and interleukin 10.
Details of reverse transcriptase polymerase chain reaction (RT-
PCR), CT scans, biochemical assays, and the development of
mobile phone-based digital contact tracing applications are
discussed in the proceeding subsections.
Molecular Method. Reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR) is a method used to
detect the presence of nucleic acid-based genetic sequences
from any organism, including viruses.36,37 To perform RT-
qPCR for SARS-CoV2, first the biological fluid where the virus
strains are present, upper and lower respiratory fluid, is
collected. The collection of fluid is generally performed using
nasopharyngeal and oropharyngeal swabs.38 Then the collected
fluid undergoes a number of filtration and separation steps to
isolate the viral RNA. Using the reverse transcriptase enzyme,
complementary viral DNA (cDNA) is generated from the viral
RNA. Specific regions of cDNA then undergo a polymerase
chain reaction for amplification, where an additional DNA
probe, designed to hybridize within a small part of the specific
region of cDNA, is incorporated to enable real-time detection
of the amplification process. Traditionally, radioactive isotopes
were used as markers to target the specific nucleic acids, but
more recently, fluorescence tags (fluorophore and a quencher)
are used on the DNA probe for the real-time detection.39
Essentially when the DNA polymerase enzyme is adding
nucleotides to the specific part of the viral cDNA, it encounters
the double-stranded DNA in its path (due to DNA probe)
where the exonuclease activity of the polymerase enzyme
separates the fluorophore and the quencher molecules to
produce real-time detection of the viral cDNA. If the number
of cDNA copies (proportional to the concentration of the
virus) produced after transcription is high, a large amount of
fluorescence signal is generated after few rounds of polymerase
reaction, and if the system is calibrated well, the fluorescence
intensity is directly proportional to the concentration of virus
in the infected patients. The typical sensitivity that can be
achieved by RT-PCR is between 500 and 1000 copies/mL of
viral RNA. Among the current tests, three regions of the cDNA
have been identified for the detection of the SARS-CoV2 virus,
which are the RdRP, E, and N genes. More details about these
sequences are described in Table 1 of the work from Udugama
et al.38 and on the Center for Disease Control and Prevention
website.40 One challenge that remains is also that SARS-CoV2
damages the target RNA when opening its viral capsid. One
reason might be due to the immune response of the host body.
This leads to a release of small fragments of RNA into the
bloodstream which is challenging for detection by RT-PCR.
Perhaps, signal enrichment strategies for isolation of RNA
fragments using advanced technologies such as CRISPR or in
combination with nanomaterials such as gold nanoparticles
and metal−organic complexes may provide a solution to this
problem. Another reason for poor sensitivity using RT-PCR is
that the RNA easily gets degraded and typically requires an
Figure 1. Structural view of SARS-CoV2 virus and its surface
protein. Reproduced with permission from ref 29 under a Creative
Commons CC-BY license. Copyright 2020 StatPearls Publishing.
Figure 2. 5’ UTR and 3’ UTR and coding region of COVID-19, SARS-CoV and MERS-CoV. Reprinted with permission from ref 34.
Copyright 2020 Elsevier.
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immediate frozen storage condition, and the completion of
handling samples may also induce the poor detection.
However, the point-of-use sensors, discussed later, may
provide an immediate testing of RNA and will overcome this
issue from the samples.
Computer Tomography. Computer tomography, which is
more popular with the name of CT scan, is being used either in
combination or as a standalone diagnostic tool to confirm the
false hits from RT-PCR for the detection of SARS-CoV2
virus.41−43 In this method, usually a large number of X-ray
measurements of the chest are taken from different angles to
generate three-dimensional (3D) images with contrast, which
are later analyzed by radiologists for abnormal features to
authenticate the presence of SARS-CoV2 infection. Signatures
of COVID-19 infection which appear in CT scan include areas
of subpleural regions of ground glass opacification affecting the
lower parts of either a single lobe or both lobes.44 In addition,
data from COVID-19 patients have shown consolidation of
fluids in the lungs. Moreover, the CT images have so far also
assisted in serving as a prognostic tool for COVID-19. For
example, in the early days (0−2 days) of the infection, the CT
scan resembles more of a normal chest condition. As the
disease progresses, the opacity of the scan increases, for
instance, patients after 4 days of the infection have been
reported with ground glass opacity which even appears as
irregular patterns in the scan. Figure 345 shows a CT scan
image from different patients on different days where the
various abnormalities are clearly visible such as focal ground
glass opacity and include bilateral and peripheral predominant
consolidation after 20 days of the onset of the disease. While
CT scans are likely to remain as one of the most important
tools in the early diagnosis of the COVID-19, the major
challenge for the radiologists lies in the distinction of
symptoms from other lung disorders or pneumonia-like
symptoms which are not due to COVID-19 infections. In
fact, the main caveat of using CT scans for COVID-19 is that
the specificity of the detection is around 25%, as reported in
the literature so far,44,46 as the imaging features overlap with
other viral pneumonia. In addition, CT scans are expensive and
require advanced technical skills for the operation and analysis,
and it can only be adapted as a complementary technology
with RT-PCR for SARS-CoV2 detection.
Biochemical Tests. Biochemical tests such as the enzyme-
linked immunosorbent assay (ELISA) have also been used to
detect the viral protein or the antibodies that are created by
our body in response to a SARS-CoV2 infection for the
diagnosis of COVID-19 disease. The standard procedure to
detect these antibodies involves the use of microtiter plates
such as the 96-well, where antibodies are detected via protein−
protein interactions. These interactions are amplified using a
fluorescence, luminescence, or colorimetric type of detection
assisted by enzymes involved in the reaction. However, one
main issue is that as the amount of viral load changes during
the course of the infection, so detecting low concentrations of
viral protein might be difficult. For instance, To et al.47 showed
salivary viral loads in the first week after the onset of
symptoms, which gradually decreased with time. On the other
hand, detecting antibodies generated in response to the viral
infection is more specific for confirming presence of the
COVID-19 disease. Nevertheless, there are still potential
challenges with developing accurate serological tests such as
those related with the cross-reactivity of SARS-CoV2 antibod-
ies with other antibodies generated against coronaviruses.48
There are still some important advantages of the antibody
testing, for instance, the presence of antibodies can verify if
vaccines are functioning as intended.49 It can also be used in
disease contact tracing applications, weeks after an individual is
infected with the virus. Perhaps currently it is the most
important test to help inform the intervention policymakers on
how many asymptomatic cases exist in a given population.50
However, false negative results from the current antibody tests
are often reported which are attributed to the combination of
following technical reasons: (1) a low concentration of
antibodies typically present in fluidic samples; (2) presence
of homologous proteins; and (3) lack of sensitivity from the
detection instrument. While, low concentration of antibodies
and the presence of homologous proteins will remain
challenging for the biosensing community, the sensitivity of
the current tools could perhaps be enhanced by development
of an engineered protein which will attach specifically to the
antibody of interest. However, the ultimate solution is the
development of ultrasensitive and selective biosensors, which
we discuss more in the proceeding sections.
Contact Tracing. Use of digital technologies, especially
smartphone-based applications to identify the presence of
infected cases, both active and recovered, has also been
implemented successfully to manage the spread of COVID-
19.51 Ferrite et al.52 recently developed an application for
contact tracing, see more in Figure 4. In this application, the
main idea is to replace a manual contact tracing with
instantaneous transmission of signals to and from a central
server. Essentially, the SARS-CoV2 virus cases are directly
communicated to the server, which enables recommendation
of risk-stratified quarantine and social distancing measures in
those now known to be possible contacts. This is done by
preserving absolute anonymity of the infected person. In
addition, tests can also be requested by symptomatic
individuals through the developed application. One of the
pros of such software-based technology is that it can easily be
tuned to be more informative, for example, quarantining areas
Figure 3. Transverse thin-section CT scans in patients with
COVID-19 disease: (A) 56 year-old man, day 3 after symptom
onset; (B) 74 year-old woman, day 10 after symptom onset; (C) 61
year-old woman, day 20 after symptom onset; and (D) 63 year-old
woman, day 17 after symptom onset. Reprinted with permission
from ref 45. Copyright 2020 Elsevier.
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if the disease spread in that area becomes uncontrolled,
quarantining specific flats or families, or performing second or
third degree contact tracing if number of cases rise. Another
advantage of contact tracing is the accessibility of technology
with members of the community. In the past few years there
has been a steady rise in the adoption of smartphones and
mobile internet which could potentially facilitate a coordinated
response during pandemics. One main limitation of contact
tracing is that to harness the full potential of the technology, it
is also necessary to increase the number of diagnostic tests.
Another limitation such as privacy consideration also exists,
which with changing time and circumstances are becoming
more acceptable within the community members.53 The use of
contact tracing however is still useful for members of a
community to track the movement of people who came in
contact with the infected, including the asymptomatic ones.
CHARACTERISTICS OF COVID-19 DISEASE FOR
DEVELOPING STRATEGIES FOR ANALYSIS
Physical Characteristics of SARS-CoV2 Virus. There are
four major structural proteins in SARS-CoV2 virus: E
(envelope protein), M (membrane protein), N (nucleocapsid
protein), and S (spike protein).54,55 Each protein not only
individually plays a role in the virus structure but also is
involved in the mechanism of the replication cycle.56 The
smallest and most enigmatic major proteins of CoV viruses is
the E protein. During the replication cycle, although a small
portion of E protein is incorporated into the virion envelope, it
is abundantly expressed inside the infected cell.57 The primary
function of the N protein is to bind to the CoV RNA genome
and to form the structure of the nucleocapsid.55 In addition, of
its major role in processes of viral genome, it involves the CoV
replication cycle and also the host cellular response to viral
infection.58 The shape of the viral envelop is defined by the M
protein.59 The other function of M protein is its role as the
central organizer in CoV assembly through interactions with
other major structural proteins.60 Coronavirus enters into host
cells by the attachment of transmembrane spike (S)
glycoprotein to the host surface receptor. Also, the S protein
mediates the subsequent fusion between the viral and host cell
membranes to make the entry of viral cell easier into the host
cell.57,61 The S protein binds to ACE2, a transmembrane
receptor which is widely expressed in the lungs, kidneys,
gastrointestinal tissue, and heart.62 The binding to the host cell
receptor and fusion between viral and cellular membranes have
been performed with two subunits of the S protein: S1 subunit
and S2 subunit, respectively.63 The S2 subunit contains
neutralizing epitopes of the virus, including a conserved fusion
peptide, a transmembrane domain, a cytoplasmic domain, and
heptad repeats 1 and 2.64 In the S1 subunit, the core receptor
binding domains are highly conserved. The differences in the
amino acids are the cause of the direct interaction between
spike protein and host cell receptor.65
Potential Small Molecule Biomarkers in Blood. A
range of small molecule biomarkers in the blood has recently
been identified for the COVID-19 detection from patients all
around the globe. While many of these biomarkers are not as
specific as detecting the viral RNA or DNA directly from the
blood or by using RT-PCR, their concentration in the blood is
found to be useful for the prognostics of the COVID-19
disease. This is due to the fact that many protein-based
molecules in the blood, which eventually serve as the
biomarkers of a disease, increase or decrease their levels in
order to fight against the infection. Therefore, some of these
biomarkers are directly linked to the severity of the infection.
Particularly, serum urea, (CREA), C (CysC) serum direct
bilirubin (DBIL), (CHE), and lactate dehydrogenase (LDH)
concentrations were found to be significantly higher in severe
COVID-19 patients than those in mild COVID-19 pa-
tients.66−68 More recently, smell dysfunction has been
proposed as a biomarker for the COVID-19 disease.69 The
mucous secretions from the nose contain many protein
molecules that help metabolize xenobiotics and support
epithelial integrity required for smell function. Therefore,
developing biosensors for the detection of mucous proteins
may also be useful for the early detection of the SARS-CoV2
infection. However, it should be noted that these biomarkers
may not be specific to COVID-19 as nasal dysfunction is
reported in other diseases such as the Parkinson’s disorder.70
More qualitative and quantitative information regarding the
trend of biomarkers for COVID-19 is summarized in Table 2.
This certainly provides first-hand information for the designer
of a biosensor to develop strategy for selecting either one or
multiple candidates to develop test platforms for precise and
accurate detection of the COVID-19 disease.
Respiratory Burst. Essentially, polymorphonuclear leuko-
cytes (PMN) circulating in our blood show elevated levels in
the blood as a defense response of the host during an episode
of infection. PMN inherit different pieces of information in the
case of different etiological agents stimulating immunity.71,72
This causes activation of PMN, and there is an increase in the
consumption of molecular oxygen which results in the
production of reactive oxygen species (ROS), a process
collectively called respiratory burst.73 Some biosensors in the
Figure 4. Contact tracing application: Using GPS contacts of
individual A and all individuals using the app, infections are traced
out. This is further supplemented by scanning QR-codes displayed
on high-traffic public amenities where GPS is too coarse. Using
this application individual A requests a test for COVID-19
infection, and their positive test result is shared as an instant
notification to individuals who have been in close contact.
Reproduced with permission under a Creative Commons CC-BY
license from ref 52. Copyright 2020 American Association for the
Advancement of Science.
ACS Nano www.acsnano.org Review
https://dx.doi.org/10.1021/acsnano.0c04421
ACS Nano 2020, 14, 7783−7807
7787
past have been developed for the ROS detection from the
virus, and on a similar basis identification of ROS from SARS-
CoV2 infection may lead to an alternative route of COVID-19
detection.74
BIOSENSORS FOR EARLY DETECTION AND
PROGNOSIS OF PANDEMIC VIRAL STRAINS
There are 11 key attributes (Figure 5):
• High selectivity: Selectivity of a biosensor is its ability to
exclusively detect the analyte in the presence of other
homologous analytes and contaminants. Viruses usually
depict similarity in their structures in that they have a
nucleic acid genome, a protein capsid which covers the
genome, and in some cases lipid covering the genome
and a protein coat.76 This protein coat in the virus
distinguishes them from the bacteria.77 Perhaps
specifically identifying and then targeting some proteins
on the capsid with other proteins via protein−protein
interactions may lead to selective detection of the
virus.78−80 A good selectivity is usually achieved by
ensuring that the monolayer of probes that target the
chosen biomarkers on the analyte is optimally
immobilized on the sensor surface.81,82 Now this is
most often a subject of research where it usually takes a
dedicated team and a time frame of 6−12 months to
develop probes specific to the target. This obviously is a
bottleneck for quick development of a biosensor during
pandemics such as the COVID-19. However, the
advancements in nanotechnology and the pace with
which discovery and invention of materials are
developing present a good opportunity for researchers
to develop chemical probes, specific only for the target
under detection.83,84 While developing specific probes is
obviously a challenge, recent work has demonstrated an
antifouling coating for the electrodes consisting of
biomolecules mixed in a network of conductive
nanomaterials.85 These layers were found to preserve
88% of the original detection signals for IL-6 even after 1
month of exposure to unprocessed human plasma.
• High sensitivity: The spacing, affinity, and specificity of
the target probes in the monolayer, often called self-
assembled monolayers (SAM) or biorecognition ele-
ments, determine the attachment of the analyte on the
sensor surface.86,87 In addition, properties of the
transducer (most often electrical or optical) influence
the overall sensitivity of the biosensor;88 for instance,
how many molecules should be attached before a
response from the sensor could easily be distinguished
from its inherent noise.89 If specificity of the SAM layer
Table 2. Potential Blood Biomarkers of SARS-CoV-2
biomarker reference range
concentration range in
COVID-19 patients ref
C-reactive protein
(CRP)
0.068−8.2 mg/L >15 mg/L 66
procalcitonin 0−0.5 ng/mL <0.1 ng/mL 66
lymphocyte count 0.8 to 4 × 109/L <0.6 × 109/L 66
interleukin-6 (IL-6) 0−7 pg/mL >15 pg/mL 66
interleukin-10 (IL-
10)
0−9.1 pg/mL >15 pg/mL 67
cystatin C (CysC) 0.6−1.3 mg/dl >1.1 mg/dl 68
serum direct
bilirubin (DBIL)
5.1−17 μmol/L >8−60 μmol/L 68
cholinesterase
(CHE)
8−18 kU/L 1.5−8 kU/L 68
lactate
dehydrogenase
(LDH)
140−280 U/L 300−600 U/L 68
creatinine (CREA) 60−120 μmol/L 30−80 μmol/L 68
urea 2.5−7.1 mmol/L 4−22 mmol/L 68
Qualitative changes in the blood profile of COVID-19 patientsa
hematologic WBC count increa-
sesneutrophil count
lymphocyte count de-
crea-
ses
platelet count
eosinophil count
hemoglobin
biochemical alanine aminotransferase increa-
sesaspartate aminotransferase
total bilirubin
blood urea nitrogen
creatinine
creatine kinase
lactate dehydrogenase
myoglobin
creatine kinase-MB
cardiac troponin I
albumin de-
crea-
ses
coagulation prothrombin time increa-
sesD-dimer
inflammatory biomarkers erythrocyte sedimentation rate increa-
sesCRP
serum-ferritin
PCT
IL-2R
IL-6
IL-8
IL-10
aThe information is adapted from the clinical studies of Henry et al.75
Figure 5. Features of an ideal biosensor required to be developed
for effective use in pandemics.
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is ensured, then it is possible to detect several small
biomarkers (sizes <150 kDa) even at the single
molecular level.90,91 For the detection of biomarkers
associated with pandemic strains such as the COVID-19,
it is of the utmost importance that the developed sensor
can detect the disease-specific biomarkers at a low
concentration, preferably at a single molecule level, and
produce an output which is easily readable for the
measured/required concentration. For instance, one
major challenge, if addressed, to detect the viral DNA
or RNA directly in whole blood without the need of
amplification via PCR technology would lead to
technologies for rapid detection of the pandemic viral
strains. Some complementary tools such as the nano-
particle-based detection tools92,93 and microfluidics94,95
might also be well-placed to address some of these
fundamental issues involving biological fluid handling on
the sensor surface to enhance sensitivity.96
• Rapid response time: For a diagnosis tool to be actively
used in a pandemic, the response time of the sensor is of
paramount importance.97 Theoretically, most trans-
ducers in the sensor respond instantaneously (<1 s) to
the applied stimulus, such as upon the interaction of
biomolecule with the sensor surface.98 However, at
times, many of these signals require post-processing with
advanced electronics and computing systems for
accurate analysis of the measured quantity. For instance,
temperature correction99 and background noise identi-
fication and removal100 can often lead to an increase in
the sensor response time. Therefore, the design and role
of signal conditional circuits are of prime importance to
ensure quick response time of the measurement.
• Multiplexing: At early stages of the infection when there
is less understanding of the characteristics of the viral
strain, it is often the concentrations of common blood
biomarkers (such as CRP and interlukien as described
for COVID-19) which serve as the signature of the
infection. As also described earlier that for COVID-19
detection, a combination of more than two biomarkers is
currently used to confirm the disease; therefore, a
multiplexed system which allows detection of multiple
biomarkers is desirable for a quick, accurate, and early
detection of the disease. Multiplexing can be achieved by
physically isolating different areas of the sensor surface,
where each isolated area acts as a standalone
sensor.101,102 Each of these individual areas could further
be made specific to one type of biomarker.103−105
Measurement can be acquired by either one transducer
which will scan the isolated areas of the sensor surface or
by incorporation of multiple transducers attached to the
individual sensing area.106,107
• Multimode sensing for on-chip validation: For the
detection of a pandemic strain, it is also necessary that
the sensor, while providing a quick response, is also
reliable. To increase the reliability in the measurement of
the sensor, more than one mode of sensing could
provide cross validation of the sensing result.107 The
major trade-off of the multimode sensing is an increase
in the size of physical dimensions and computation time
of the sensor. This can also lead to a slow response time,
increased power consumption, and cost ineffectiveness.
However, the good news is that most of these barriers
are rapidly being addressed. Electrochemical and optical
techniques on single platforms108 which can easily be
translated into multiplexed panels are increasingly
getting attention in both academia and industry, which
might be able to serve the purpose of increased reliability
and robustness required in the healthcare sensors, by
instant authentication of the measured data.
• Disposable: The fact that the pandemic viral strains are
highly infectious, for example, COVID-19 has a
reproductive number higher than that established for
SARS and H1N1, that is, between 1.5 and 2, the need
for single-use sensors is crucial for avoiding contami-
nation from the sensing systems. The most judicial
pathway to develop a disposable sensor system is the
modular approach.109−111 In this approach, electrode
and readout modules can be separately designed where
electrodes can be made cost-effective and disposable in
nature. Candidate materials for developing disposable
electrodes could potentially include glass-,112
paper-,113,114 plastic-,115,116 metal-,117,118 or ceramic-
based119 materials which can be used to immobilize
bioprobes specific to the biomolecules of our interest.
Among these materials, paper-based biosensing electro-
des,112,113 which have grabbed the attention of the
community in recent times, provide the most optimal
disposable features, as such electrodes could be classified
into burnable trash after use. On the other hand, readout
modules in the form of a mobile phone application-
based120 readout will provide many advantages other
than cost-effectiveness, such as periodic data collection
and connectivity to the centralized healthcare systems.
• Long shelf life and easy to use: The electrodes developed
should be easy to use, and their lifetime should be at
least 1 month. This will ensure that a large number of
testing kits can be prepared and shipped not only to the
healthcare facilities but also to the supermarket
shelves.121,122 The ease of use could allow people to
self-test and take necessary and informed decisions to
self-isolate, which will ensure that the transmission of the
disease can be curtailed at its source.
• Cost effective: The advantage of cost-effectiveness of a
biosensor is effectively reflected in its affordability.123
Intuitively, the lower the price of a given biosensor, the
more affordable is the device. To keep the price low, so
that all members of the community can afford it during
pandemics, a biosensing system can essentially be
divided into two parts: The first part can be a disposable
electrode such as the screen printed electrode or a
paper-based electrode, which could potentially be
available in the supermarket drug shelves.124,125 The
electrode could have direct contact with a body fluid
such as saliva for the quick detection of viral strain. The
second part of the sensor system can be an application
on a mobile phone which can essentially serve the
purpose of a direct readout of signals from the
sensor.126,127 Such applications could potentially be
made available by the government or healthcare
government body of the affected region or community.
On the other hand, a standalone readout and data
acquisition system with data loggers for disposable
sensors can also be developed, which could be equipped
in hospitals or at border control posts of a country.128
Certainly there are some biosensors that are now easily
available in the supermarkets such as the pregnancy test
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strips and lateral flow strips for sexually transmitted
disorders and for glucose meters.125 It is on similar lines
that sensors which can rapidly detect viral infection, if
developed, could turn out to very useful for self-testing
of infectious diseases. In addition, this would decrease
the load on the public health bodies to detect the disease
in a large-sized population, which could also lead to
timely control of the disease spread.
• Mass manufacturing: During pandemics, there is an
urgent and large demand for sensors that can detect the
fast spreading disease accurately and quickly. Due to lack
of availability and reachability of a number of sensors,
low rates of testing compared to total population are
reported in the case of COVID-19, even in the nations
with world leading heath infrastructures.129,130 In an
ideal situation, the number of biosensors is equal to the
population number of a given geographical area under
test to ensure that all potential members of the
community that can spread the disease are identified
at an early stage. While there is a significant
technological challenge to mass-produce sensors, the
latest advancements in the manufacturing such as the 3D
printing131 and machine molding132 can help in the
development of a large number of sensors in a very short
duration of time.
• Autonomy and connectivity to central healthcare
systems: Autonomy in the biosensing system would
ensure a high compatibility between electrodes and the
readout modules. Along with autonomy, measurement
systems of a sensor in pandemics should be able to
connect itself with the central database of a hospital
which will collect real-time data from the measurements.
For instance, a mobile phone application which collects
the data from the sensor can be integrated with a two-
way communication channel to (1) send data to the
central database and (2) provide prompt therapeutic
intervention or facilitate the situation with dispatched
paramedical staff.133−135 Networked healthcare service
can also maintain and troubleshoot by additional
information about the functionality of a sensor.
Furthermore, location, positive disease cases, personal
details such as age, gender, and contact information
could easily be logged on to the central databases. This
would provide the government and health care policy
markers with real-time data to quickly and accurately
determine necessary actions, such as locking down
certain locations to contain and mitigate the fast spread
of the disease.52
Among the 11 key attributes discussed above, the most
important focus of current biosensing innovations should be
the sensitivity and specificity of the assays directed toward
early detection of COVID-19 disease or future pandemic
strains. This is necessary to overcome the uncertainty
associated with a wide variety of advanced testing technology
including lateral flow assays or direct detection of viral RNA
with CRISPR biosensors.136 Repurposing some of the
instrumentation such as the 96-well microtiter plate readers
could also potentially provide multiple replicates of a bioassay
in a short duration of time. Such absorbance readers are so
common that nearly all laboratories which provide routine
blood profile testing, including in the remote settings, may
utilize this platform for quick testing. For instance, absorbance
readers are used in recent work on the quick detection of
COVID-19 disease,137 suggesting that the capital required for
new schemes developed already exists within many test
facilities. Another important aspect which could potentially
lead to a quick solution required in mid-pandemics is the use
of soft-biosensing. For instance, artificially intelligent software
could be installed in hand-held thermometers which are
currently being widely used in the screening of COVID-19
candidate patients. Software could perhaps be developed in
such a way that the infrared signals analyzed by the detector
provide information on some key skin biomarkers, in addition
to the temperature measurement, similar to non-invasive
biosensing.138−140
Electronic Sensors for COVID-19. Field-effect-transistors
(FETs) and three-electrode potentiometric and amperometric
systems are the key electronic biosensors widely applicable in
the detection of biomolecules and pathogens. The main
advantages of an electronic biosensor are miniaturization, low
Figure 6. Detection of SARS-CoV2 using FETs: The schematic shows a collection of biological samples from a patient and its application on
the graphene-based sensing area of the FET biosensor. Binding events associated with the SAR-CoV2 virus can be captured by the sensor in
real time. Reprinted with permission from ref 153. Copyright 2020 American Chemical Society.
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cost, and mass manufacturing. Besides, the concepts of a
modular sensor for separating electrode and readout on a
smartphone can be implemented effectively. FETs for instance
are easily fabricated in CMOS foundaries,141−143 whereas a
large number of electrochemical sensors are now commercially
available in the market in portable formats.144,145 In the past a
large number of electrochemical sensors have been developed
for pandemic viral strains. For instance, Han et al. developed a
single microfluidic electrochemical sensor for the detection of
H1N1, H5N1, and H7N9 combined with zinc oxide
nanorods,146 amplification strategies for sensitive detection of
H1N1 with electrochemical sensors by Li et al.,147 electro-
chemical detection of MERS using carbon electrodes by
Layqah et al.,148 detection of SARS by Iskhikawa et al.,149 and
many other works which even used disposable screen printed
electrodes and paper-based substrates for the detection of viral
strains.150−152 Some of these works have definitely encouraged
researchers to develop strategies for the early detection of
COVID-19 disease. The work of Seo et al. reported a FET
biosensor for detecting SARS-CoV2 in clinical samples.153 This
sensor was produced by coating the gate of the transistor made
up of graphene sheets, with an antibody that was specific
against the SARS-CoV2 spike protein. Desired performance of
the sensor was identified with tests conducted with antigen as
protein, cultured virus, and nasal swab specimens from
COVID-19 patients. The biosensor could detect the SARS-
CoV2 spike protein at concentrations of 1 fg/mL in buffer
solvents prepared in the laboratory and 100 fg/mL from the
biological fluid of the clinical samples. This biosensor was
further used for the successful detection of viral strains in
culture medium with a limit of detection in clinical samples
found around 2.42 × 102 copies/mL. This was indeed a neat
example of how biosensors can detect the virus at low
concentration without sample pretreatment or labeling, see
more details in Figure 6. In another recent work, Mahari et al.
developed a biosensor using three electrode-electrochemical
systems by using disposable screen-printed carbon electro-
des.154 The limit of detection of this biosensor named,
eCovSens, was found to be 120 fM in buffer solvents. Even
though the detection was performed in nonclinical samples, the
electrodes were found stable for up to 4 weeks, suggesting that
such electrodes could potentially be mass-produced, shipped,
and then distributed in the community within a reasonable
time frame during the mid-pandemics.
Optical Biosensors for COVID-19. A large number of
optical biosensors primarily based on the principle of
plasmonics,155 essentially where the transduction principles
use optical components such as waveguides,156 fiber optics,157
photonic crystals,158 and lasers159 are classified into optical
sensors. Optical biosensors such as the surface plasmon sensors
(SPR), including the localized surface plasmon resonance
(LSPR), are commercially available since early 1990s,160 and
they have been widely used to detect viral strains such as those
associated with H1N1,161 SARS,162 MERS,163 and influenza164
in laboratory settings.
While many of the developed plasmonic techniques with
advanced surface chemistry provide high sensitivity, selectivity,
and quick response time for the detection of the viral strains,
their use in point-of-care applications remains challenging.
This is due to the large size and cost of the instrumentation
which is involved in the development of plasmonic systems.
Even though the use of these sensors remains elusive for the
mass production and self-testing by community members,
these sensors are now well-developed for widespread use in
laboratory-based settings for accurate detection of viral strains
during pandemics. Recently, Qiu et al. have developed a
biosensor for accurate diagnosis of COVID-19 disease where
plasmonic photothermal (PPT) effect and LSPR are combined
as transduction principles in the sensing scheme.165 Essentially,
the DNA receptors are used to detect selected sequences from
the SARS-CoV2 through nucleic acid hybridization. With the
mandatory use of nanoparticles and light in LSPR sensing,
there is a generation of well-known thermoplasmonic at the
plasmonic resonance frequency. The authors claim to elevate
the in situ hybridization temperature using this thermoplas-
monic heat which further assists in facilitating accurate
discrimination of two similar gene sequences. This LSPR
biosensor showed a good limit of detection, down to the
concentration of 0.22 pM, exhibiting a high sensitivity toward
the selected SARS-CoV-2 sequences in a multigene mixture;
see more details in Figure 7.
It should be noted that with current advancements in the
nanofabrication166 and combination of LSPR with micro-
fluidics,167 further enhancement of sensitivity and potential
integration in portable formats is feasible.168,169 Therefore,
LSPR holds a great potential to improve the diagnostic
accuracy in the clinical tests and relieve the pressure on PCR-
based tests that usually need a well-equipped laboratory and
well-trained personnel, which usually remains challenging due
to a shortage of resources during pandemics.
In addition to the direct sensing of analytes which confirm
viral infection, optical sensors can also play a significant role in
high-resolution imaging of the viruses during pandemics. For
example, Wei et al. demonstrated how optical sensors can be
used for virus imaging based on the laser diode excitation.170
The developed system is in the form of an optomechanical
attachment which can easily be integrated to the existing
camera module of a smart phone, see more details in Figure 8.
The special resolution of the imaging platform is <50 nm,
allowing easy detection of individual viruses using a
smartphone.
Figure 7. LSPR detection of nucleic acid sequences from SARS-
CoV2 virus. The schematic shows the architecture of LSPR
substrate consisting of gold nanoparticles where light is
illuminated on the substrate for generation of local heat and
detection of binding nucleic acid binding events. The graph also
shows the LSPR response to the theroplasmonic effect and toward
detection of nucleic acid sequences at low concentrations.
Reprinted with permission from ref 165. Copyright 2020 American
Chemical Society.
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BIOSENSORS FOR DRUG ANALYSIS AND
ACCELERATING DRUG DISCOVERY FOR VACCINES
As biosensors provide detailed information on the binding
affinity of the biomolecules to a given substrate and their
associated kinetics, their use in drug discovery applications is
ubiquitous. In addition, as the design of a given transducer can
be tuned according to its intended application, different types
of biosensors can be implemented in various levels of the drug
discovery process to enhance the discovery of a potential
vaccine.171 In addition, as viruses evolve,172,173 the need for a
new drug is also inevitable, and it is in this context where
sensing technologies can provide a solid backbone to bear the
burden of a timely discovery of new drugs to contain an
outbreak of a disease. In the drug discovery process, the
research and development phase of the drug discovery process
normally takes 3−5 years, preclinical studies take 1−2 years,
and clinical trials take 2−3 years, followed by review and
approvals which take over 6 months to 1 year.174 Time of these
stages can significantly be reduced with the use of advanced
bio/chemical sensing technologies. We provide key attributes
of biosensors specific to the drug discovery stages that can
possibly assist in speeding up the drug discovery process:
• Ligand fishing: Identification of potential drugs from
natural resources such as the plant extracts is a critical,
challenging, and time-consuming task in the process of
drug discovery.175 For example, discovery of a bioactive
constituent from traditional Indian and Chinese
medicines has contributed to their well-known ther-
apeutic effects in viral diseases, including for SARS
CoV2-virus.176−178 Identification of such bioactive
compounds has largely been dependent on techniques
such as ultrafiltration,179 liquid chromatography
(LC),180 and mass spectrometry (MS),181 known as
ligand fishing. It is in this context that all biosensors
represent themselves as a useful tool for the discovery of
bioactive compounds from a complex mixture of natural
products while providing enhanced efficiency and
reduced sample preparation time at a low cost as
compared to the existing techniques such as the LS and
MS. While biosensors combined with the nanomaterials
have also shown high selectivity toward the targets,
sensors for screening active compounds from natural
products have not been reported so far. However, by
combining biosensors with microfluidics, it is possible to
develop such tools due to common procedures such as
incubation,182 washing,183 mixing,184 and compartmen-
talization185 of the solution being easily achieved by
microfluidics systems.
• High-throughput screening of candidate drug com-
pounds: In contrast to the extraction of compounds
from the natural products, in laboratory synthesis of
chemical compounds for possible use as drugs, the
ability of the compound to affect the identified target
using biosensors can be tested. Here high-throughput
array-based sensing technologies such as the
FETs186−188 surface plasmon sensors189,190 have an
advantage over the conventional techniques of LS and
MS where effectively more than 10,000 compounds can
be screened in 1 week as compared to 3−4 years of
testing. In addition to compound screening, cross-
reactive activity of the candidate compounds,191 to
check their interfere with other homologous targets,
could also be tested using such sensing platforms. An
example of a high-throughput biosensor chip consisting
9000 electrodes is shown in Figure 9.
• Affinity and kinetics: Affinity and kinetics information
on a compound is vital in understanding its use as a
potential drug.192 For instance, biosensors can closely be
made to perform experiments based on the bioinfor-
Figure 8. Imaging single viruses using a smartphone. A
smartphone-based optomechanical attachment with a resolution
of <50 nm for the detection of individual viruses. Reprinted with
permission from ref 170. Copyright 2013 American Chemical
Society.
Figure 9. High-throughput biosensor: This example shows (A)
microelectrode array used for cell detection; (B) sensor layout and
the addressing scheme employed in the CMOS sensor chip; (C)
complete CMOS packaged biochip; and D) microphotograph
showing 9000 electrodes in the chip. Reprinted with permission
from ref 188. Copyright 2012 Elsevier.
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matics modeling algorithms.193 In preclinical trials,
sensing platforms can assist in evaluating the binding
affinity and kinetics of the antibodies or to assess the
developed vaccine to the target protein or loci on the
virus. Statistically relevant information on affinity and
kinetics can also be generated in a short duration of time
with use of multiplexed biosensing arrays.194
• Monitoring chemical parameters in the pharmaceutical
production process: The production of drugs operates in
a stringent safety, sterility, and precision-oriented
environment. Therefore, use of biosensors in monitoring
chemical parameters such as pH, temperature, and
enzymatic activity in real time during the process of drug
production is significant to improve the quality of the
drugs.195 Other bio/chemical sensors which measure
gases such as oxygen and concentration of byproducts in
the process are also useful in the identification of
physical and chemical errors in the production line of
the drugs.196 A significant challenge and opportunity for
some of the advanced biosensors is to essentially
integrate themselves in the production line in the form
of a sensor network. Further, with integration of
machine learning programs, data from these biosensors
could potentially be used to improve the delivery time of
drugs in large quantities required during pandemics.197
• Bedside drug monitoring in hospitals: Another signifi-
cant opportunity for biosensors in pandemics is in drug
analysis by biomedical systems equipped along the
bedside in the hospitals.198,199 An appropriate quantity
of drug injected in the body of the patient can
significantly improve the recovery time of the patient.
Most often, it is essential to monitor various parameters
of the body such as the blood pressure, heart rate,
temperature, oxygen concentration, and other small
molecules in the blood profile.200 Establishing a real-
time relationship between concentrations of aforemen-
tioned parameters is essential, and this is where
biosensors, if combined with the internet of technology,
can effectively be used for the measurement and analysis
of drugs in real time.
MICROFLUIDIC BIOSENSORS FOR PANDEMICS
Microfluidics is a technique for precise control and
manipulation of microscale fluids.201 The basic operation
units such as preparation, extraction, reaction, and detection in
various analysis processes are integrated on a microchip.
Through the micromachining process, the micro- to
submillimeter-level fluid channels, pumps, valves, sensors,
detectors, and other units can be fabricated on the substrate
of silicon, metal, polymer, or other materials. So far,
microfluidic platforms have been applied using various
analytical techniques including electrochemical analysis,
fluorescence analysis, MS, and chemiluminescence.202 Micro-
fluidic platforms can be classified into capillary, pressure-
driven, centrifugal, electrokinetic, and acoustic systems on the
basis of their liquid propulsion principles.203 In the past
decades, microfluidic biosensors have been developed for the
detection of infectious diseases in the medical field. Infectious
diseases are usually identified by bacteria (e.g., Streptococcus
agalactiae, Escherichia coli, Haemophilus inf luenza), food borne
pathogens (e.g., salmonella, listeria, cholera toxin), and viruses
(e.g., hepatitis C, influenza, dengue virus).204 For example,
shear horizontal surface acoustic wave biosensors were
established for multiplex detection of anti-p24 and anti-gp41
antibodies of HIV.205 The designed dual-channel biochip
consists of a sensing area sensitive to biological binding events,
along with in situ reference control coating and miniaturization
configuration. The microfluidic biosensor can detect HIV
biomarkers within 5 min using only 6 μL of plasma sample,
which raises the prospects of the next generation of
economical, rapid, and point-of-care diagnosis to prevent
HIV pandemics. A silicon nanowire-based microfluidic
biosensor was also developed to detect the RT-PCR product
of dengue serotype 2.206 A detection limit as low as 10 fM was
reported within 30 min, which was 3 orders of magnitude
lower than that obtained by using 32P-labeled probes and 4
orders of magnitude lower than that achieved by ethidium
bromide staining. During the COVID-19 pandemic, rapid
diagnosis is of great significance in early diagnosis of SARS-
CoV2 for timely and appropriate treatment. Although culture-
based methods and molecular techniques are commonly used
in clinical diagnosis, recently introduced microfluidic bio-
sensors have the advantages of cheapness, portability, rapid
response, high precision, high reproducibility, low reagent/
sample consumption, easy application, and high-throughput
parallel processing.207 Therefore, microfluidic biosensors can
meet the World Health Organization guidelines “ASSURED”
(e.g., affordable, specific, sensitive, user-friendly, rapid and
robust, equipment free, and deliverable to end user),208 which
have tremendous potential to be implemented for SARS-CoV2
detection in point-of-care COVID-19 diagnosis. However,
further efforts should be devoted to improving sensitivity and
specificity, strengthening stability and efficiency, and short-
ening fabrication time and analysis time for monitoring
pandemics. It is also necessary to reduce the matrix effects of
actual samples. Moreover, it remains challenging to develop
fully automated microfluidic biosensors for on-site monitoring
of pandemics.
WASTEWATER BIOSENSORS FOR EARLY WARNING
OF OUTBREAK
Wastewater-based epidemiology (WBE) has been imple-
mented for the determination of various biomarkers, including
illicit and licit drugs, pharmaceuticals, and personal care
products, markers of population size, industrial chemicals, and
biologicals.209,210 Human viruses (e.g., astroviruses, enter-
oviruses, noroviruses, rotaviruses, salivirus) have also been
detected in wastewater, indicating that WBE holds great
potential in the early determination of viral outbreaks by
routinely monitoring the concentration and diversity of viruses
in wastewater.211 Generally, WBE can provide information
about viruses on a population scale and assess the temporal
and spatial trends of virus occurrence in the watershed within
the catchment of sewage treatment plants. The outbreak of
COVID-19 caused by SARS-CoV2 has brought about a
significant risk to human health. It has been suggested that
SARS-CoV2 can be detected in fecal samples of confirmed
COVID-19 cases from many countries including China,211,212
United States,213 Germany,214 Singapore,215 and Korea.216
The research involving 10 pediatric COVID-19 confirmed
cases provided the potential evidence for fecal viral shedding of
SARS-CoV2.217 Even if the results of the nasopharyngeal
testing became negative, the rectal testing of eight children was
still positive, indicating that viral shedding of gastrointestinal
tract and fecal−oral transmission might occur. The presence of
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SARS-CoV2 in fecal samples may increase the virus load on
the wastewater systems of infected cities.
Recent evidence suggests that determination of SARS-CoV2
in wastewater is helpful to study the virus transmission in
humans since SARS-CoV2 can be excreted in feces or urine.
Several attempts have been made to detect SARS-CoV2 in
wastewater including the Netherlands,218 United States,219
France,220 Australia,221 Spain,222 and Sweden. The report of
SARS- CoV2 detection in sewage was published by Gertjan
Medema et al.218 in the Netherlands. Specifically, the targets of
gene N (N1−N3) and gene E were tested by RT-qPCR in the
WWTP sewage samples to determine the presence of SARS-
CoV2. Neither gene N nor gene E was detected on February 6,
while gene N1 was detected in six sites, and genes N3 and E
were detected in five and four sites on March 15 and 16,
respectively. This is consistent with the first case in the
Netherlands reported on February 27. In the United States,
SARS-CoV2 at high titers was determined by RT-PCR in
wastewater samples from a major urban treatment facility in
Massachusetts.217,218 Their work demonstrated that longitudi-
nal analysis of wastewater can provide an estimate of the
population level of SARS-CoV2 burden without available on-
site testing. The appearance of SARS-CoV2 RNA was verified
in six WWTP wastewater samples from a low prevalence area
Murcia in Spain.222 Compared to the COVID-19 cases
announced by the municipality, the environmental surveillance
results clarified that SARS-CoV2 had spread among the
population before the initial cases were reported in many cities.
Therefore, WBE could be used as an early warning tool for the
presence and prevalence of COVID-19 infections and provide
a more accurate estimate of the spread extent of COVID-19
infections than clinical testing.223 RT-PCR assays have been
routinely employed for SARS-CoV2 detection in numerous
research and disease control centers since the outbreak of
COVID-19,223 as also discussed in our aforementioned
sections. However, RT-PCR has some disadvantages which
may limit its applications globally. For example, complete
facilities, expensive equipment, skilled technicians, and
laborious procedures are essential for RT-PCR. With the
rapid growth of COVID-19 confirmed cases worldwide, this
method has been unable to meet the requirements of detecting
numerous suspicious cases in a short time even though in some
cases, PCR has demonstrated high sensitivity and specificity.
Essentially, the requirements for complicated sample handling
in the laboratory, skilled personnel, and a long period of data
processing and analysis (4−6 h) are not conducive to real-time
and effective monitoring of samples on location. Therefore, it
is critical to develop efficient transportable and robust
analytical tools to accurately and quickly trace low-level
SARS-CoV2 sources through WBE to confirm these suspected
cases and screen asymptomatic infected cases without
centralized laboratories. Using a WBE strategy in creating an
early warning and intervention system will require a rapid
biosensing method for the on-site detection of viruses at the
wastewater collection outlets.209,212 We have recently proposed
the use of a paper-based device which can be used for WBE, as
developed in our previous work,224 see Figure 10 for more
details. Recent advances on signal amplification strategies have
also lead to enhanced sensitivity in paper-based analytical
devices for various sensing applications.225 Due to the
advantages of low cost, rapidness, sensitivity, specificity,
accuracy, and simplicity, biosensors have been applied in
detecting different analytes for clinical diagnosis, food safety,
and environmental monitoring. Recently, biosensors have been
employed for electrochemical, optical, electrical, thermal,
acoustic, and piezoelectric determination of infectious diseases
such as AIDS, dengue, Ebola, influenza, and malaria. The
biomarkers of these infectious diseases are usually identified in
blood, feces, plasma, serum, sputum, saliva, urine and nasal
mucosa. When detecting wastewater samples, the matrix effects
of the wastewater can also be minimized using an ultrahigh-
affinity probe for specific targets.226 Moreover, biosensors can
be extended for the multiplex detection of infectious diseases.
For instance, Men et al.227 presented a multifunctional
fluorescent protein nanowire (FNw) for multiplex detection
of hemagglutinin 1 protein from the influenza virus along with
p24 and gp120 protein from HIV. The FNw integrated with
numerous green fluorescent protein molecules could amplify
signal and enhance sensitivity. In addition, biosensors can be
developed into integrated medical devices for point-of-care
detection of infectious diseases in resource-limited regions. For
example, Choi et al.228 presented an integrated paper-based
sample-to-answer biosensor for nucleic acid testing. The fast
technology analysis (FTA) card and glass fiber were integrated
into a lateral flow strip for nucleic acid extraction,
amplification, eye detection, and smartphone quantification.
A hand-held battery-powered heating device was also used for
LAMP amplification in POC settings. Hence, biosensors can
be employed as early warning sensing systems to help the
government take effective measures in advance to prevent the
spread of infectious diseases.
Biosensors hold potentials for in situ quantitative analysis of
SARS-CoV2 in wastewater. Although wastewater is a complex
matrix, we have recently proposed a paper-based device which
Figure 10. Design of an integrated sensor for the detection of
multiplex infectious disease pathogens. (a) Components of the
sensor and (b) illustration of the complete sample processing from
sample introduction to pathogen detection. Reprinted with
permission from ref 224. Copyright 2018 American Chemical
Society.
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has shown great potential to detect pathogens in wastewater.
Essentially, we developed a fast “sample-to-answer” analysis
method which can provide quantitative monitoring of nucleic
acids and genetic information through the analysis of sewage
waste.229 Our results were further cross validated with a robust
electrophoresis and agarose gel image assay, showing
promising reliability for wastewater analysis. The proposed
biosensors will show advantages including affordability, rapid
analysis time, excellent sensitivity, superior specificity, and low
reagent/sample consumption. These benefits highlight the
biosensors’ extraordinary capability of economical, portable,
and user-friendly detection of SARS-CoV2 in wastewater
compared to traditional detection methods. Biosensors will
help identify COVID-19 infected patients on the spot to
provide timely medical advice and monitor the spread of
SARS-CoV2 at early stage. Therefore, sewage sensors for
SARS-CoV2 detection at the population level have a clear
potential for early warning of COVID-19 pandemic. For
example, a recent study demonstrated that live SARS-CoV2
was isolated from the feces and urine of infected people, which
would then enter the wastewater treatment system.230
Although SARS-COV-2 is usually present in sewage in the
form of RNA particles, there currently is no evidence which
shows live SARS-CoV-2 present in sewage. Within this
viewpoint, further research on the environment for the analysis
of disease biomarkers is required to effectively use WBE
biosensors for an informed status of the disease within a
community.
NANOSCALE VISUALIZATION AND
CHARACTERIZATION TOOLS
There are three principal techniques commonly used
individually or in combination for the direct visualization,
diagnosis, and characterization of virus structure: XRD
analysis, EM, and AFM. The exceptional capabilities of these
instruments allow not only in-depth analysis of virus structure
and function but also investigation of viral impact on host cells
and extracellular environment, useful in drug discovery
applications.28,231−241
Electron Microscopy. An EM is a tool that uses a beam of
accelerated electrons as a source of illumination. Due to the
short wavelength of electrons in comparison with visible light
photons (up to 100,000 times), the resolving power of EM is
higher than optical microscopes and can visualize the structure
of particles at nanometer scales. The capability of EM to reveal
the structures of nanoparticles makes it a powerful instrument
for detection, diagnosis, and analysis of viruses (as viruses are
of the same scale as that of many inorganic nanoparticles such
as gold, extensively used in research). In comparison, with the
molecular and serological approaches used for virus diagnosis
which require specific probe to recognize virus, EM methods
do not need organism-specific reagents for recognizing the
pathogenic agent. It means for the case of an unknown disease,
molecular tests need information about the potential agents to
determine the appropriate tests, while EM provides an open
view of whatever might be present in a given sample under
investigation.237 Besides the capability of EM in direct
detection of virus by visualization, it provides information
about the ultrastructure of the virus, its structural dynamics
related to the attachment, and replication processes. This
makes EM a useful tool in the discovery and design of antiviral
agents and vaccines.236−238,242,243 The main techniques of EM
microscopy to analyze the virus structures are negative
staining, thin sectioning, immune electron microscopy
(IEM), cryoelectron microscopy (cryo-EM), tomography,
and scanning electron microscopy (SEM). In negative staining,
the background is stained, leaving the actual specimen
untouched and thus visible. Thin sectioning is used to reduce
the viruses into thin layers to be transparent for electrons. The
principle of IEM is the formation of immune complexes of the
virus with its associated antibody. The cryo-EM is an imaging
procedure used to generate high-resolution 3D images of
samples, commonly biological materials and cells. In this
method, a series of two-dimensional (2D) images of sample are
captured while it is tilted at different angles, and then, the 2D
images are merged to reconstruct 3D image.243−245 On the
other hand, SEM has also been used for virus quantification
procedures.246 It should be noted that SEM if combined with
the abilities of transmission electron microscopy (TEM) can
also provide high-resolution images of virus structure with
minute structural details for improved characterization of
viruses.237 In the past using EM techniques, SARS was
classified as a coronavirus.247,248 EM was used in the
recognition of MERS,249 and the image of COVID-19 virus
was taken by TEM,250,251 see Figure 11 for more details.
Recently cryo-EM was used to describe multiple monoclonal
antibodies targeting SARS-CoV2, specific to the S protein
identified from memory B cells, from an individual who was
infected with SARS-CoV in 2003.42 One antibody, named
S309, potently neutralizes SARS-CoV2 and SARS-CoV. Using
cryo-EM and binding assays, it was also revealed that S309
recognizes a glycan-containing epitope which is conserved
within the sarbecovirus subgenus, without competing with the
receptor attachment.250 In ref 252, the cryo-EM is used to
determine a 2.9 Å-resolution structure of the RNA-dependent
RNA polymerase nsp12 of CoV 19, which catalyzes the
synthesis of viral RNA, in complex with two cofactors, nsp7
and nsp8. In ref 253, the 3D structure of the causative agent in
SARS infection and the comprehensive information about the
morphological surface of SARS-CoV was obtained. This
included enhanced visualization of the trimeric structure in
the 10−20 nm spikes of the virus surface. These results support
the characterization of the SARS agent and development of
antiviral strategies,253 and we envisage that such techniques
can easily be extended to reveal the details of CoV 19 viruses.
Figure 11. Visualization of SARS-CoV2 with TEM. The virus is
shown in blue color. Reprinted with permission from ref 38.
Copyright 2020 American Chemical Society.
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X-ray Crystallography. The XRD from single crystals is a
promising method to obtain the highest resolution of the virus
structure and visualize the macromolecular assemblies at an
atomic level. Generally, there are five steps to identify the virus
structure using X-ray crystallography techniques which
include: preparation and purification of virus particles,
crystallization and mounting the particle crystal, measurement
of diffracted data, calculation of phase through molecular
replacement (MR) or isomorphous replacement,254,255 and
finally, map interpretation and building the model.256−258
To prepare and purify the viruses from the extracellular/
tissue culture media, purification kits are readily accessible
from the commercial sources.259 During the preparation steps,
to maintain the icosahedral symmetry of the virus, the handling
procedures should be performed as gentle as possible.
Following the purification stage, crystallization is required to
bring the aqueous protein solution to supersaturation. There
are two phases in crystallization: nucleation and growth. In
nucleation, the crystal nucleus is formed at the critical size of
molecular aggregation, then a subsequent process of growth is
initiated. For growing the crystals of virus samples, there are
four methods, batch crystallization, dialysis, liquid−liquid
diffusion, and vapor diffusion.260
To improve the resolution and prevent the secondary
radiation damage to the virus sample in the collection process
of X-ray data, the crystallographic data are collected at
cryogenic temperature, typically around 100 K. Growing
high-quality virus crystal is one of the challenges in X-ray
crystallography of the virus particles. Methods currently in use
are time-consuming and based on trial and error procedures.
Nevertheless, cryo-EM/ET can be a powerful complementary
method for virus protein crystallography.261 Information
provided by 3D cryo-EM can be integrated with the collected
X-ray data to improve the built model of virus particles.262
Serial femtosecond crystallography (SFX) is another type of
X-ray crystallography that uses X-ray free-electron lasers
(XFELs). Due to the pulse duration in femtosecond and
unparalleled brilliance of XFEL beams, this technique is useful
to study the viruses as both a crystal and single particle. Using
time-resolved SFX, the changes during life cycles of viruses
such as their response to the variation of pH and viral protein
interaction with the receptors can be detected.234,263−265
Therefore, the combination of high-resolution static structure
of viruses obtained by cryo-EM and dynamic results of
conformational changes at room temperature using SFX can be
a breakthrough toward producing time-resolved virus struc-
tures.266 The use of X-ray crystallography methods to study the
family of coronaviruses shows the ability of the tool for in-
depth analysis of COVID-19.267−269 Recently, in ref 270, the
3D crystal structure of the SARS-CoV2 unliganded Mpro at
1.75 Å resolution is determined (see Figure 12 for more
details), and it was used to guide the optimization of a series of
α-ketoamide inhibitors. Such structural analysis forms a strong
basis for further development of these compounds to antiviral
drugs. However, both common EM and XRD methods are
based on the averaging of the numerous particles present in the
electron micrographs or crystal. Therefore, there is a limitation
in the information obtained from these structural differences
that can exist between the individual particles in a large
population. Besides, these methods require environments
which are far away from the physiological conditions in
which the virus normally operates and precludes the
characterization of their dynamic properties in real time.
This complicates structural studies of viruses that lack a well-
defined symmetry such as the SARS-CoV2 as an enveloped
virus. A third, direct imaging technology that provides
significant impact on virus study is AFM. AFM provides
possibilities for studying the COVID-19 virus particles,
complementing classical EM and XRD studies.
Atomic Force Microscopy. AFM has become a powerful
instrument for the visualization and characterization of
nanoscale imaging of samples in air and in liquid.271 Typically,
in AFM measurement, the deflection of microcantilever is used
to probe the interaction between the surface of the sample and
the nanometric tip located at the end of microcantilever. Based
on the time scales, type, and range of interaction, an extensive
range of information including atomistic details of the surface,
mechanical, physical, chemical, thermal, and viscoelastic
properties of nano/bio materials can be obtained.272−287 The
earliest invented mode of AFM was the contact mode, where
the tip is raster scanned through the sample surface while
maintaining a constant force applied to the sample through
deflection detection by adjusting the height of the tip. The
main challenges in using contact mode to image soft materials
such as viruses and other biological specimens is the applied
force to avoid the reversible or irreversible deformation,
unwanted friction, and damage to the sample.288 To improve
the image resolution and minimize the applied force and
friction, the dynamic AFM was invented.289 Generally, in
dynamic AFM, the microcantilever is oscillated usually close to
its resonance frequency while scanning the sample surface.
Two major dynamic AFM modes are amplitude modulation
atomic force microscopy (AM- AFM) (also known as tapping
mode) and frequency modulation atomic force microscopy
(FM-AFM).289 In the dynamic mode, due to the decrease of
the contact time between tip and sample to the small fraction
of oscillation period, the friction is minimized and the risk of
damage to the sample is significantly reduced. In addition, of
these two common modes of dynamic AFM, recently, several
advanced techniques are developed to increase the resolution
and explore more information from the materials during
imaging. Due to the dynamic nature of these advanced
techniques, they can be classified as multifrequency meth-
ods,281,289 where the cantilever is excited at different
frequencies and different signals are used as feedback
Figure 12. The 3D structure of SARS-CoV2 Mpro, in two different
views. One protomer of the dimeriz shown in light blue and the
other one in orange. Amino acid residues of the catalytic site are
indicated as yellow and blue spheres, for Cys145 and His41,
respectively. Black spheres indicate the positions of Ala285 of each
of the two domains III (see text). Chain termini are labeled N and
C for molecule A (lightblue) and N* and C* for molecule B
(orange). Reproduced with permission under a Creative Commons
CC-BY license from ref 270. Copyright 2020 American Association
for the Advancement of Science.
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parameters.25 In addition to the ability to visualize and image
virus particles, AFM has the capability to measure and quantify
the mechanical and structural properties of virus par-
ticles.290,291 Moreover, AFM can be used to manipulate and
dissect biological materials including viruses.292−295
To extract and quantify viscoelastic, chemical, and physical
properties of viruses, the force−distance curve-based AFM
(FD-based AFM) and recently multifrequency approaches are
the common methods. In modern FD curve-based AFM,
numerous FD curves are recorded during imaging the
biological sample.296 Based on the principle of FD-based
imaging, the method to map chemical and biological properties
is developed.297,298 In this method, the tips are functionalized
by specific ligands. Then, based on the adhesion and
mechanical strength of bonds formed between functionalized
tip and receptors of the samples, the biological properties can
be explored during imaging.25,291 The main challenge of FD-
based AFM is the high volume and time of data acquisition.25
To increase the speed of imaging and reduce the amount of
collected data during measurement, high-speed AFM and
multifrequency methods are invented.299,300 Several multi-
frequency AFM methods have been proposed, however due to
their complex physical principle, theoretical development and
mechanism of interpretation of data are under more
investigation.299,301 The previous studies of coronaviruses
using AFM techniques302−305 show the significant potential of
AFM to image, visualize, and explore the morphological
features of the SARS-CoV virus; see Figure 13 as a typical
AFM characterization. Generally, visualization/characterization
devices are useful as they provide following information: (1)
quantify the surface and subsurface properties of the affected
cell by COVID-19 in real time; (2) detect multiple dynamic
interactions between SARS-CoV2 virus and host cell; and (3)
study the mechanism of SARS-CoV2 virus to cross the cellular
membrane and deliver its genome inside the host cells and (4)
its replication inside cell and characterization of the nucleic
acids of SARS-CoV2 virus, to understand how it is condensed
and packaged inside capsids. Recent proposed techniques to
nanoscale map directional flow patterns also can be used to
study the effects of different pH and ion-specific sieving
properties of the host cell on the binding of S protein of SARS-
CoV2 virus with receptor at the surface of the cell.306 In fact,
very recently Yang et al. characterized molecular binding and
inhibition interactions of SARS-CoV2 with ACE2 receptors
with AFM.307
TECHNOLOGY AND POLICIES
While academia has made tremendous progress in the field of
biosensors, a major challenge remains in overcoming the
difficulties associated with translating the laboratory research
quickly into commercially viable prototypes by industry and
addressing the complex regulatory issues required for clinical
settings, especially during pandemics. The good news is that
slowly the technology transfer investments from government
and industry is on the rise. In addition, regulatory policies from
the government in many countries are becoming increasingly
business friendly with the academics. This is evident from the
fact that a lot of organizations are now identifying and bridging
gaps between the academic research and industrial needs via
workshops and university-funded proof-of-concept projects.
Moreover, specialized urgent funds without limits are set up by
many governments during an infectious disease outbreak such
as for the COVID-19. On the other hand, instrumentation
such as SPR, AFM, XRD, and EM, while well-established and
developed from the infrastructure viewpoint, has a high cost
which limits its use mostly to laboratory testing.308,309 Still,
large-scale industries, especially the ones involved in the
vaccine development and testing, can potentially reveal
morphological features.310
Figure 13. (A) 2D and (B) 3D AFM images and contour map (C) of a single SARS-CoV virion. Scale bar = 100 nm in (A) and (C). The
corresponding cursor profiles (middle and bottom row) provide quantitative measurements of the dimensions for the spike proteins (1−15)
displayed in (C). Reprinted with permission from ref 302. Copyright 2020 John Wiley and Sons.
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However, one significant challenge in the technology
transfer of most of the biosensors and advanced instrumenta-
tion is the capacity building of human resources. The main
reason is that practical hands on skills from subjects which are
fundamentally far from each other such as biology and
electronics are often required with the operator of the sensing
instrumentation. This limitation is also being addressed by
many educational institutions where courses and projects are
encouraged to be interdisciplinary in nature. Other technical
challenges for fast technology transfer during pandemics which
remain elusive are quick adoption of the biosensor
manufacturing protocols and reliability of the sensors. As
most of the quickly developed technologies are customized for
the pandemic strains, reproducibility, stability, and reliability
tests can take more than a few months of time to generate
statistical data for making informed decisions. It is here that
fundamental science and engineering need to further discover
materials which are inherently physically and chemically stable
and invent technologies to provide more reliability in the
measurements.
In addition, modular sensing systems also provide a
flexibility in usage for different analytical biomarkers. For
instance, in a single measuring module, electrodes could
potentially be used for the detection of multiple biomarkers of
a pandemic strain by simply changing the biorecognition layer
or the surface chemistry on the electrode. On the other hand,
translation of nanoscale analytical technologies to clinical
settings depends on the ability to simplify complex analytical
devices for non-experts to use and control. Automation and
remote control of devices, which is fast increasing with the
advent of the internet of healthcare technology, might provide
solutions whereby quick troubleshooting or assistance in
calibration can be provided to the medical staff (user)
remotely and easily.
ETHICS AND TECHNOLOGY ADOPTION
While the innovative sensing technologies have immense
potential to revolutionize the healthcare system during a crisis
such as the COVID-19, there are important ethical issues
revolving around such technologies. Arguments concerning
data confidentiality, ownership, and privacy are extremely
challenging to address in a short duration of time, leading to a
decrease in the adoption of the technology by community
members.311,312 Especially, the sensors which aim to provide
immediate, detailed, and objective feedback of the measure-
ment remotely to the information management systems must
abide to the data protection legislatures of the given region.
Even though passing the quality controls related to the data
protection has nowadays become fast, the acceptability of these
technologies in terms of their reliability remains low. Many
medical staff still have concerns whether the developed
technology has enough understanding of the biology to be
properly informed from the measurement. Moreover, with
traditional medicine, before a doctor provides a treatment, they
must seek a patient’s consent to reasonably inform them about
the risks and benefits associated with the intended treatment.
In this context, the risks and benefits of the mobile heath
applications and self-use biosensors are not explicit as most
often users are less willing to read the terms and conditions
which usually pop up while using an application. However,
toward the laboratory-based testing, biosensors and surface
characterization tools eliminate ethical issues such as those
associated with animal and human testing.313,314 For example,
if a drug is required to be developed in a short duration during
a pandemic, large-scale testing can potentially be performed on
high-throughput sensing platforms before it is considered
viable to test on animals and humans. Large-scale testing could
include a variety of characterizations to reveal molecular
affinity, specificity, and cross reactivity with potential
compounds inside the organism. Therefore, with the increased
use of modern characterization tools and bio/chemical sensors,
large uncertainties associated with quick drug development and
testing can potentially be eliminated.
CONCLUSIONS
Biosensors and nanoscale visualization/characterization tools
can be considered as innovative and promising tools that can
lead to life saving decisions on treatment and a deep
understanding of pandemic strains. As we have witnessed
extreme challenges associated with the testing and validation of
viruses in COVID-19, we need to be prepared in terms of
diagnostics to prevent a spread of any new emerging infectious
diseases. Recently, Narvaez et al. suggested seven main
recommendations for biosensing community, including the
funding agencies: (1) investment; (2) collaboration; (3) mass
manufacturing; (4) devices should comply with regulation
bodies such as FDA; (5) rigorously satisfy features such as
disposability and low sample volume tests; (6) integrate with
Internet Of Things (IOT), and (7) ease of use for members of
the community.315 With the rapid advancement of nano-
technology, we believe that the sensing mechanism will emerge
with a multidisciplinary approach, to enable rapid and on-site
detection of viruses for point-of-care diagnosis and prevent
epidemics at an early stage.
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VOCABULARY
Soft-biosensor, Portable devices which utilize noncontact
modes such as direct thermal imaging to detect biomolecules
or disease signatures and subsequent analysis to provide the
status of the disease using a customized software-based
application right at the site of patient; mHealth, The practice
of medicine and public health supported by mobile devices
such as smartphones, tablets, personal digital assistants, and the
wireless infrastructure; for example, contract tracing applica-
tions can be put in mHealth category of devices; Wastewater-
based epidemiology (WBE), A bio/chemical sensing
approach for analysis of pollutants and biomarkers in raw
wastewater to obtain both qualitative and quantitative data on
the activity of all inhabitants within a given wastewater shed;
Serial femtosecond crystallography (SFX), A type of X-ray
crystallography technique developed using X-ray free-electron
lasers (XFELs) which includes multiple progress in sample
delivery, data analysis, and collection; Immune electron
microscopy (IEM), Any method which uses molecules in
interaction with antibodies in coincidence with electron
microscopy to localize antigens or at the ultrastructural level;
Multifrequency AFM, A collection of methods where the
microcantilever is excited with a range of frequencies and
corresponding signals at different frequencies are detected to
be used as feedback parameters and information channels to
explore the materials properties; FD-based AFM, The force−
distance curves obtained from measuring the vertical force that
the tip applies to the surface. This technique can be used to
extract mechanical, chemical, and physical properties of
nanomaterials and is the basis of probing the ligand−receptor
bonds in physiological conditions
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